Valuation: enGene Therapeutics Inc.

Market Cap 125M 109M 101M 93.24M 177M 11.93B 180M 1.21B 471M 5.84B 468M 458M 20.27B P/E 2026 *
-1.07x
P/E 2027 * -1.22x
Enterprise Value -76.64M -67.22M -62.06M -57.35M -109M -7.34B -111M -746M -290M -3.59B -288M -281M -12.47B EV / Sales 2026 *
-
EV / Sales 2027 * -0.47x
Free-Float
99.91%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: enGene Therapeutics Inc.

1 day-3.12%
1 week+9.09%
Current month+10.98%
1 month+16.36%
3 months-73.73%
6 months-77.41%
Current year-78.74%
1 week 1.78
Extreme 1.7841
1.96
1 month 1.57
Extreme 1.57
1.96
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
47.17
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 2024-07-21
Chief Tech/Sci/R&D Officer 55 2023-04-23
Director of Finance/CFO 52 2023-11-26
Director TitleAgeSince
Director/Board Member 57 2023-08-07
Chairman 68 2024-05-14
Director/Board Member 66 2023-12-17
Date Insider Type Main position Quantity % Market Cap.
06-15Option

Director

31,000 0.0463%
06-15Option

Director

31,000 0.0463%
06-15Option

Executive/Senior Manager

200,000 0.2986%
Change 5-day change 1-year change 3-year change Capi.($)
-2.34%+9.09%-49.87%-82.16% 125M
-0.38%-3.44%+71.35%+126.62% 56.71B
+4.91%-3.30%+71.97%+92.14% 51.3B
+1.42%+5.74%+22.33%+478.48% 25.26B
-0.23%-4.45%-16.62%-13.25% 23.65B
+3.93%+7.11%+44.20%-1.96% 18.69B
+2.01%+2.99%+40.72%-24.46% 17.71B
-6.84%+4.81%+201.88%+348.11% 17.7B
-0.92%+8.90%+38.48% - 14.26B
+1.37%+1.96%+29.21%+198.61% 14.1B
Average +0.18%+4.20%+45.37%+124.68% 23.95B
Weighted average by Cap. +1.04%+2.16%+58.39%+142.79%

Financials

2026 *2027 *
Net sales - 6.17M 5.41M 5M 4.62M 8.75M 591M 8.92M 60.05M 23.33M 289M 23.17M 22.66M 1B
Net income -119M -104M -96.13M -88.83M -168M -11.37B -172M -1.16B -449M -5.56B -446M -436M -19.31B -119M -104M -96.25M -88.94M -169M -11.38B -172M -1.16B -450M -5.57B -446M -437M -19.33B
Net Debt -201M -177M -163M -151M -285M -19.27B -291M -1.96B -761M -9.43B -756M -739M -32.73B -127M -112M -103M -95.39M -181M -12.21B -184M -1.24B -482M -5.97B -479M -468M -20.74B
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
82
Date Price Change Volume
26-07-06 US$1.920 +0.52% 1,409,129
26-07-08 US$1.860 -3.12% 1,521,143
26-07-07 US$1.920 +0.52% 1,409,129
26-07-06 US$1.910 +7.30% 2,866,895
26-07-02 US$1.780 +1.14% 588,354
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
1.860USD
Average target price
3.286USD
Spread / Average Target
+76.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ENGN Stock